Skip to main content
Terug
Watch Compare

KIORA PHARMACEUTICALS INC

Datakwaliteit: 100%
Ook genoteerd als KPHMW Nasdaq
KPRX
Nasdaq Manufacturing Chemicals
€ 2,49
▼ € 0,37 (-12,94%)
Marktkapitalisatie: 9,84 M
Prijs
€ 2,49
Marktkapitalisatie
9,84 M
Dagbereik
€ 2,45 — € 2,77
52-Weeksbereik
€ 1,77 — € 4,18
Volume
356.718
Openen € 2,67
50D / 200D Gem.
€ 2,09
19,38% above
50D / 200D Gem.
€ 2,40
3,61% above

Quick Summary

Belangrijkste Punten

Earnings declined -401,42% over the past year
Negative free cash flow of -10,07 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)-100,00%
Earnings (1Y)-401,42%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-48,66%
Boven sectorgemiddelde (-53,41%)
ROIC-36,17%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio8,79
Interest Coverage-642,84

Waardering

PE (TTM)
-0,91
Boven sectorgemiddelde (-1,48)
P/B Ratio0,44
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,9 -1,5
P/B 0,4 1,6
ROE % -48,7 -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -100,00% Revenue Growth (3Y) N/A
Earnings Growth (1Y) -401,42% Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -10,84 M
ROE -48,66% ROA -35,06%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -10,07 M
ROIC -36,17% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 8,79
Interest Coverage -642,84 Asset Turnover 0,00
Working Capital 20,11 M Tangible Book Value 15,72 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,91 Forward P/E N/A
P/B Ratio 0,44 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -102,39%
Market Cap 9,84 M Enterprise Value 4,33 M
Per Share
EPS (Diluted TTM) -2,64 Revenue / Share 0,00
FCF / Share -2,55 OCF / Share -2,52
EPS CAGR (1Y) -403,45% EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 92,96%
SBC-Adj. FCF -10,91 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 16,02 M — — 0,0
Net Income -10,84 M 3,59 M -12,51 M -13,58 M -16,39 M
EPS (Diluted) -2,64 0,87 -2,69 -18,55 -1,77
Gross Profit — — — — —
Operating Income -12,83 M 4,51 M -12,59 M -12,31 M -16,94 M
EBITDA — — — — —
R&D Expenses 10,78 M 7,84 M 4,03 M 3,45 M 5,35 M
SG&A Expenses — — — — —
D&A 24.801,0 19.205,0 51.798,0 41.609,0 45.296,0
Interest Expense 19.960,0 21.446,0 11.132,0 8.599,0 6.851,0
Income Tax -1,28 M 2,07 M 90.319,0 -113.010,0 -304.781,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 24,25 M 36,48 M 13,71 M 18,68 M 18,06 M
Total Liabilities 8,13 M 10,72 M 7,60 M 7,27 M 8,83 M
Shareholders' Equity 16,13 M 25,76 M 6,11 M 11,41 M 9,22 M
Total Debt — — — — 278.190,0
Cash & Equivalents 8,70 M 3,79 M 2,45 M 5,96 M 7,85 M
Current Assets 21,75 M 29,71 M 4,74 M 7,68 M 8,99 M
Current Liabilities 3,63 M 6,01 M 1,63 M 3,27 M 1,61 M